

タファミジスは心アミロイドーシスの死亡率を低下させる(Abstract 3235)

ATTR-ACT: トランスサイレチン型心アミロイドーシスの生存率を改善する初めての治療が開発される

ATTR-ACT: Researchers discover first treatment to improve survival in transthyretin amyloid cardiomyopathy

タファミジスはトランスサイレチン型心アミロイドーシスと呼ばれる、まれな心疾患の生存率を改善し入院を減らす初めての治療薬である。とのレイトブレイキング研究が ESC Congress 2018 で発表され、*New England Journal of Medicine* に掲載された。ATTR-ACT トライアルにおいて、タファミジスはプラセボと比較して死亡および心血管疾患関連の入院を有意に減少させた($p=0.0006$)。30か月の追跡期間中、実薬群の78人(29.5%)が死亡したのに対し、プラセボ群では76人(42.9%)が死亡した。この結果には、心臓移植施行患者や補助人工心臓を使用した患者も含まれた。この治療薬はまた、プラセボと比較し6分間歩行距離の低下およびQOLの低下を減少させた。

Full Text

Tafamidis is the first treatment to improve survival and reduce hospitalizations in a rare heart condition called transthyretin amyloid cardiomyopathy, according to late breaking research presented in a Hot Line Session at ESC Congress 2018 and published in the *New England Journal of Medicine*.

Professor Claudio Rapezzi, principal investigator, University of Bologna, Italy, said: "There are no medications specifically approved for the treatment of transthyretin amyloid cardiomyopathy. Tafamidis improved survival and quality of life, and reduced hospitalizations, indicating that it could be an effective therapy for these patients. A submission to the regulatory authorities for marketing approval is in process as a consequence of this study."

Transthyretin amyloid cardiomyopathy is a rare, progressive, fatal disease. The hereditary form is caused by mutations in the TTR gene and typically presents in 50–70 year-olds, while the acquired (wild-type) form presents in 60–80 year-olds. The disease is caused when the transport protein, transthyretin, becomes unstable and misfolds, leading to the formation of amyloid, which is deposited in the heart. This causes the heart muscle to become stiff and results in heart failure.

Patients have debilitating symptoms common to heart failure, such as shortness of breath, fatigue, orthostatic hypotension, and syncope, leading to frailty and poorer quality of life. Patients survive an average of three to five years after diagnosis. There are no approved drugs to improve survival, and therapy is limited to managing symptoms.

Tafamidis stabilizes transthyretin, preventing misfolding and the formation of amyloid. Treatment with this therapy delays neurologic progression in transthyretin familial amyloid polyneuropathy, a similar condition in which amyloid is deposited in the nerves after transthyretin misfolding. The drug is approved for this condition in the EU.

The medicine has not been approved for the treatment of transthyretin amyloid cardiomyopathy, but has orphan drug designation from the European Medicines Agency (EMA) and Fast Track designation from the US Food and Drug Administration (FDA).

The ATTR-ACT trial assessed the efficacy and safety of tafamidis in patients with hereditary and acquired transthyretin amyloid cardiomyopathy. The trial enrolled 441 patients aged 18–90 years from 48 centers in 13 countries. Patients were randomized in a 2:1:2 ratio to tafamidis 80 mg, tafamidis 20 mg, or placebo – all taken orally, once a day, for 30 months.

The primary endpoint was the hierarchical combination of all-cause death and cardiovascular-related hospitalizations from baseline to 30 months. The two tafamidis groups were combined and compared with the placebo group. Secondary outcomes included the change from baseline to 30 months in exercise capacity (assessed with the six-minute walk test) and in health-related quality of life (assessed using the Kansas City Cardiomyopathy Questionnaire).

A total of 264 patients received the drug and 177 received placebo. Tafamidis significantly reduced death and cardiovascular-related hospitalization compared to placebo ($p=0.0006$). During the 30-month follow-up, 78 (29.5%) patients receiving the medicine died compared to 76 (42.9%) receiving placebo – this included patients who underwent heart transplant or received a cardiac mechanical assist device as these were classified as death in the analysis. Rates of cardiovascular-related hospitalizations were 52.3% and 60.5% in the tafamidis and placebo groups, respectively.

The therapy also reduced the decline in six-minute walk distance and quality of life compared with placebo. The incidence of individual adverse events were similar or fewer with drug treatment. Discontinuations of study drug due to treatment-related adverse events were less common with tafamidis than placebo.

Professor Rapezzi said: "ATTR-ACT is the largest randomized clinical trial in patients with transthyretin amyloid cardiomyopathy to date. The trial showed that tafamidis is superior to placebo in reducing the risk of death and cardiovascular-related hospitalizations. Tafamidis also reduced the decline in functional capacity and quality of life and had a favorable safety profile in these patients."

He concluded: "These findings provide strong evidence that tafamidis is an effective therapy for patients with transthyretin amyloid cardiomyopathy and can modify the natural history of this disease."

SOURCES OF FUNDING: Pfizer.

DISCLOSURES: Claudio Rapezzi MD has received research grants, speaker fees and board participation honoraria from Pfizer.

Conference News

[News 01]

一次予防に対するアスピリンの価値に関する様々なメッセージ

[News 02]

糖尿病における一次予防に対しアスピリンは必要ない

[News 03]

HDLコレステロール値が非常に高いことは有害である可能性がある

[News 04]

降圧薬により長期生存率が改善する

[News 05]

魚油は糖尿病患者における心血管イベントを予防しない

[News 06]

持久系アスリートにおいて左房線維化増加が認められた

[News 07]

左心系心内膜炎において経口抗菌薬への切り替えは安全である

[News 08]

心房細動における併用療法に疑念が生じた

[News 09]

タファミジスは心アミロイドーシスの死亡率を低下させる

[News 10]

心房細動患者において未知の脳障害が認められた

[News 11]

小径冠動脈病変に対するバルーンとステントの比較

[News 12]

フェブキシスタットは高尿酸血症患者の有害事象を減少させる

[News 13]

悪化する心不全においてトロンビン阻害薬は無効である

[News 14]

抗肥満薬は心血管イベントを増加させない

[News 15]

認知機能検査で認知症リスクの高い高血圧患者を同定できる

[News 16]

就寝時にヨガ音楽を聴くことは心臓によい

[News 17]

たこつぼ心筋症患者においてがんは予後不良と関連がある

[News 18]

抗凝固薬による出血はがんと診断されるリスクを上昇させる